Table 1.

Presenting features and clinical course information among ten patients with chronic phase chronic myeloid leukemia (CP-CML) harboring sole BCR::ABL1 e1a2 (P190) transcripts.

Variables	All patients (n = 10)
Age in years at diagnosis; median (range)	63 (50–83)
Females, n (%)	6 (60)
Leukocytes × 109/L; median (range)	58 (19.3–175)
Absolute monocyte count × 109/L; median (range)	7 (0.8–29.6)
Blood monocyte %; median (range)	12 (3–21)
Absolute eosinophil count × 109/L; median (range)	0.8 (0.3–8.4)
Blood eosinophil %; median (range)	2 (1–7)
Absolute basophil count × 109/L; median (range)	0.9 (0.06-4.2)
Blood basophil %; median (range)	2.5 (0.46-5)
Absolute myelocyte count × 109/L; median (range)	3.3 (0-29.7)
Blood myelocyte %; median (range)	5.5 (0-3)
Blood blast count × 109/L; median (range)	0.9 (0-4)
Blood blast %; median (range)	1 (0-2)
Bone marrow blast %; median (range)	1 (0–2)
Bone marrow reticulin fibrosis grade; median (range)	0 (0-1)
Hemoglobin g/dL; median (range)	12.5 (10–14.4)
Platelets × 109/L; median (range)	209 (118–479)
Philadelphia chromosome karyotype at time of diagnosis, n (%)	100%
No. of metaphases analyzed; median (range)	20 (20–25)
Metaphases involved, (n)
100%	7
80%	1
35%	2
Palpable splenomegaly, n (%)	2 (20)
Symptoms at time of diagnosis seen in 2 or more patients:
Asymptomatic, n (%)	5 (50)
Fatigue, n (%)	3 (30)
Abdominal discomfort, n (%)	2 (20)
Tyrosine Kinase Inhibitor response at any time:
Complete hematologic response (CHR), n (%)	10 (100)
Complete cytogenetic response (CCyR), n (%)	8 (80)
Major molecular response (MMR), n (%)	5 (50)
Follow-up period from diagnosis in years; median (range)	6 (1–16)
Deaths, n (%) Both deaths were unrelated to CML	2 (20)
Progression to Acute Myeloid Leukemia, n (%)	0 (0)
Allogeneic hematopoietic stem cell transplant, n (%)	0 (0)